A significant decrease in tumor volume was noted after treatment with PARPi in both 22RV1-SCRM and 22RV1 MALAT1 KO groups; however, the percentage reduction in tumor volume was more pronounced in the MALAT1-KO group (∼80%) compared with the 22RV1-SCRM (∼55%) at day 20 upon treatment with PARPi (Fig. 7A and B). Here, MALAT1 is linked to neoplasm.